Corrigendum to “Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score” [Eur. Urol. 83(5) (2024) 432–440] (European Urology (2023) 83(5) (432–440), (S030228382300026X), (10.1016/j.eururo.2023.01.016))

Matthew D. Galsky; Dean F. Bajorin; Johannes Alfred Witjes; Jürgen E. Gschwend; Yoshihiko Tomita; Federico Nasroulah; Jun Li; Sandra Collette; Begoña P. Valderrama; Marc Oliver Grimm; Leonard Appleman; Gwenaelle Gravis; Andrea Necchi; Dingwei Ye; Frank Stenner; Megan Wind-Rotolo; Joshua Zhang; Keziban Ünsal-Kaçmaz

doi:10.1016/j.eururo.2023.12.013

Corrigendum to “Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score” [Eur. Urol. 83(5) (2024) 432–440] (European Urology (2023) 83(5) (432–440), (S030228382300026X), (10.1016/j.eururo.2023.01.016))

Matthew D. Galsky, Dean F. Bajorin, Johannes Alfred Witjes, Jürgen E. Gschwend, Yoshihiko Tomita, Federico Nasroulah, Jun Li, Sandra Collette, Begoña P. Valderrama, Marc Oliver Grimm, Leonard Appleman, Gwenaelle Gravis, Andrea Necchi, Dingwei Ye, Frank Stenner, Megan Wind-Rotolo, Joshua Zhang, Keziban Ünsal-Kaçmaz

Chair of Urology

Research output: Contribution to journal › Comment/debate

2 Scopus citations

Abstract

The authors regret that there are two errors displayed in Table 1 which require correction. The median age for patients in the CPS <1 group treated with placebo should be corrected to 68.0 years. In addition, the percentage of patients in the CPS <1 group treated with placebo with tumor origin at initial diagnosis of renal pelvis should be corrected to 29%. The corrected table is shown below. The authors would like to apologise for any inconvenience caused.

Original language	English
Pages (from-to)	e96-e97
Journal	European Urology
Volume	85
Issue number	3
DOIs	https://doi.org/10.1016/j.eururo.2023.12.013
State	Published - Mar 2024

Access to Document

10.1016/j.eururo.2023.12.013

Fingerprint

Dive into the research topics of 'Corrigendum to “Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score” [Eur. Urol. 83(5) (2024) 432–440] (European Urology (2023) 83(5) (432–440), (S030228382300026X), (10.1016/j.eururo.2023.01.016))'. Together they form a unique fingerprint.

Cite this

Galsky, M. D., Bajorin, D. F., Witjes, J. A., Gschwend, J. E., Tomita, Y., Nasroulah, F., Li, J., Collette, S., Valderrama, B. P., Grimm, M. O., Appleman, L., Gravis, G., Necchi, A., Ye, D., Stenner, F., Wind-Rotolo, M., Zhang, J., & Ünsal-Kaçmaz, K. (2024). Corrigendum to “Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score” [Eur. Urol. 83(5) (2024) 432–440] (European Urology (2023) 83(5) (432–440), (S030228382300026X), (10.1016/j.eururo.2023.01.016)). European Urology, 85(3), e96-e97. https://doi.org/10.1016/j.eururo.2023.12.013

Galsky, Matthew D. ; Bajorin, Dean F. ; Witjes, Johannes Alfred et al. / Corrigendum to “Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score” [Eur. Urol. 83(5) (2024) 432–440] (European Urology (2023) 83(5) (432–440), (S030228382300026X), (10.1016/j.eururo.2023.01.016)). In: European Urology. 2024 ; Vol. 85, No. 3. pp. e96-e97.

@article{54b07f341da44cb5b221c10dc7ff2ba4,

title = "Corrigendum to “Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score” [Eur. Urol. 83(5) (2024) 432–440] (European Urology (2023) 83(5) (432–440), (S030228382300026X), (10.1016/j.eururo.2023.01.016))",

abstract = "The authors regret that there are two errors displayed in Table 1 which require correction. The median age for patients in the CPS <1 group treated with placebo should be corrected to 68.0 years. In addition, the percentage of patients in the CPS <1 group treated with placebo with tumor origin at initial diagnosis of renal pelvis should be corrected to 29%. The corrected table is shown below. The authors would like to apologise for any inconvenience caused.",

author = "Galsky, {Matthew D.} and Bajorin, {Dean F.} and Witjes, {Johannes Alfred} and Gschwend, {J{\"u}rgen E.} and Yoshihiko Tomita and Federico Nasroulah and Jun Li and Sandra Collette and Valderrama, {Bego{\~n}a P.} and Grimm, {Marc Oliver} and Leonard Appleman and Gwenaelle Gravis and Andrea Necchi and Dingwei Ye and Frank Stenner and Megan Wind-Rotolo and Joshua Zhang and Keziban {\"U}nsal-Ka{\c c}maz",

note = "Publisher Copyright: {\textcopyright} 2023 The Author(s)",

year = "2024",

month = mar,

doi = "10.1016/j.eururo.2023.12.013",

language = "English",

volume = "85",

pages = "e96--e97",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier B.V.",

number = "3",

}

Galsky, MD, Bajorin, DF, Witjes, JA, Gschwend, JE, Tomita, Y, Nasroulah, F, Li, J, Collette, S, Valderrama, BP, Grimm, MO, Appleman, L, Gravis, G, Necchi, A, Ye, D, Stenner, F, Wind-Rotolo, M, Zhang, J & Ünsal-Kaçmaz, K 2024, 'Corrigendum to “Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score” [Eur. Urol. 83(5) (2024) 432–440] (European Urology (2023) 83(5) (432–440), (S030228382300026X), (10.1016/j.eururo.2023.01.016))', European Urology, vol. 85, no. 3, pp. e96-e97. https://doi.org/10.1016/j.eururo.2023.12.013

Corrigendum to “Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score” [Eur. Urol. 83(5) (2024) 432–440] (European Urology (2023) 83(5) (432–440), (S030228382300026X), (10.1016/j.eururo.2023.01.016)). / Galsky, Matthew D.; Bajorin, Dean F.; Witjes, Johannes Alfred et al.
In: European Urology, Vol. 85, No. 3, 03.2024, p. e96-e97.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Corrigendum to “Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score” [Eur. Urol. 83(5) (2024) 432–440] (European Urology (2023) 83(5) (432–440), (S030228382300026X), (10.1016/j.eururo.2023.01.016))

AU - Galsky, Matthew D.

AU - Bajorin, Dean F.

AU - Witjes, Johannes Alfred

AU - Gschwend, Jürgen E.

AU - Tomita, Yoshihiko

AU - Nasroulah, Federico

AU - Li, Jun

AU - Collette, Sandra

AU - Valderrama, Begoña P.

AU - Grimm, Marc Oliver

AU - Appleman, Leonard

AU - Gravis, Gwenaelle

AU - Necchi, Andrea

AU - Ye, Dingwei

AU - Stenner, Frank

AU - Wind-Rotolo, Megan

AU - Zhang, Joshua

AU - Ünsal-Kaçmaz, Keziban

PY - 2024/3

Y1 - 2024/3

N2 - The authors regret that there are two errors displayed in Table 1 which require correction. The median age for patients in the CPS <1 group treated with placebo should be corrected to 68.0 years. In addition, the percentage of patients in the CPS <1 group treated with placebo with tumor origin at initial diagnosis of renal pelvis should be corrected to 29%. The corrected table is shown below. The authors would like to apologise for any inconvenience caused.

AB - The authors regret that there are two errors displayed in Table 1 which require correction. The median age for patients in the CPS <1 group treated with placebo should be corrected to 68.0 years. In addition, the percentage of patients in the CPS <1 group treated with placebo with tumor origin at initial diagnosis of renal pelvis should be corrected to 29%. The corrected table is shown below. The authors would like to apologise for any inconvenience caused.

UR - http://www.scopus.com/inward/record.url?scp=85182451082&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2023.12.013

DO - 10.1016/j.eururo.2023.12.013

M3 - Comment/debate

C2 - 38176992

AN - SCOPUS:85182451082

SN - 0302-2838

VL - 85

SP - e96-e97

JO - European Urology

JF - European Urology

IS - 3

ER -

Galsky MD, Bajorin DF, Witjes JA, Gschwend JE, Tomita Y, Nasroulah F et al. Corrigendum to “Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score” [Eur. Urol. 83(5) (2024) 432–440] (European Urology (2023) 83(5) (432–440), (S030228382300026X), (10.1016/j.eururo.2023.01.016)). European Urology. 2024 Mar;85(3):e96-e97. doi: 10.1016/j.eururo.2023.12.013

Abstract

Access to Document

Other files and links

Fingerprint

Cite this